National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020)
| Autor: | O.Yu. Vinogradova, T.A. Ageeva, V.V. Baikov, A L Melikyan, Elena V. Morozova, S.V. Gritsaev, Tatiana Mitina, Boris V. Afanasyev, K. D. Kaplanov, Alla M. Kovrigina, Yu. V. Shatokhin, A.Yu. Zaritskey, I N Subortseva, E.S. Polushkina, Anna G. Turkina, T. I. Pospelova, Vasily Shuvaev, Elza Lomaia, Valeriy G. Savchenko, Roman G. Shmakov, A B Sudarikov, Sokolova Ma, Tatyana Ionova, Irina Martynkevich |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Clinical oncohematology. 14:262-298 |
| ISSN: | 2500-2139 1997-6933 |
| DOI: | 10.21320/2500-2139-2021-14-2-262-298 |
| Popis: | The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms comes in response to the need to standardize the approach to diagnosis and treatment. The availability of clinical guidelines can facilitate the choice of adequate treatment strategy, provides practicing physicians with exhaustive and up-to-date information on advantages and shortcomings of different treatment methods as well as lets health professionals better assess expected extents of treatment required by patients. In 2013 a working group was formed to develop and formulate clinical guidelines on the treatment of myeloproliferative neoplasms. These guidelines were first published in 2014, afterwards they were revised and republished. The dynamic development of current hematology presupposes constant updating of knowledge and implementation of new diagnosis and treatment methods in clinical practice. In this context clinical guidelines present a dynamic document to be continuously amended, expanded, and updated in accordance with scientific findings and new requirements of specialists who deal directly with this category of patients. The present edition is an upgraded version of clinical guidelines with updated information on the unification of constitutional symptoms assessment using MPN-SAF TSS questionnaire (MPN10), on applying prognostic scales in primary myelofibrosis, assessing therapy efficacy in myeloproliferative neoplasms, revising indications for prescription, on dose correction, and discontinuation of targeted drugs (ruxolitinib). The guidelines are intended for oncologists, hematologists, healthcare executives, and medical students. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|